3628 results for «886»
3628 results
Complications and bailout strategies in transcatheter mitral interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.
Transcatheter electrosurgery and leaflet modification of the aortic valve
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...
Re-intervention challenges after first aortic valve replacement
19 May 2026 – From EuroPCR 2026
Addressing the challenges of re-intervention after initial aortic valve replacement, this session highlights advanced valve-in-valve TAVI strategies, including leaflet modification techniques, management of extreme coronary obstruction risks, and complex anatomical considerations such as post-Bentall root anatomy.
Managing life-threatening TAVI complications
19 May 2026 – From EuroPCR 2026
Manage life-threatening complications in TAVI procedures with a structured algorithm for identification and resolution. This session shares expert tips for handling specific severe complications and reviews best practices aimed at complication avoidance to enhance patient safety and procedural success.
Bioresorbable devices in clinical practice
19 May 2026 – From EuroPCR 2026
This session examines the evolving role of bioresorbable devices in coronary intervention, showcasing hybrid PCI strategies, novel applications in myocardial bridging, and innovative solutions for complex coronary lesions, including the use of bioadaptors and dual-device techniques.
All we need to know about vulnerable plaque
19 May 2026 – From EuroPCR 2026
Understand the critical importance of vulnerable plaque identification and management. This session covers optimal strategies for detecting vulnerable plaques, their prognostic implications, and evidence-based treatment approaches illustrated through detailed case presentations.
Primary PCI in challenging anatomy
19 May 2026 – From EuroPCR 2026
Focusing on primary PCI in challenging coronary anatomies, this session covers intracoronary thrombolysis for ectasia, imaging-guided no-stent strategies in vein graft occlusions, and management of coronary aneurysms presenting with acute coronary syndromes, highlighting tailored interventional approaches.
Rescue PCI for acute or unusual left main lesions
19 May 2026 – From EuroPCR 2026
This session explores rescue PCI techniques for acute and unusual left main coronary lesions, highlighting complex cases such as left main compression syndrome in pulmonary hypertension, and challenging strategies in acute coronary syndromes with left main occlusion and anatomical variations.
Next generation TAVI procedural planning
19 May 2026 – From EuroPCR 2026
Explore the forefront of TAVI procedural planning, featuring innovations such as valve-in-valve techniques for sutureless valves, integration of artificial intelligence in heart team decisions, and advanced imaging-guided access methods. The session also examines clinical outcomes related to bicuspid anatomy and prosthesis-patient mismatch, providing a comprehensive view...
Selecting PCI devices in specific scenarios
19 May 2026 – From EuroPCR 2026
This session addresses device selection strategies tailored to specific interventional cardiology scenarios. It covers innovative approaches such as coronary laser use in difficult lesions, intravascular imaging-guided treatments for in-stent restenosis, and physiological assessment post-magnesium scaffold resorption, supported by real-world data and emerging machine learning applications.
Optimal management of primary PCI complications
19 May 2026 – From EuroPCR 2026
This session delves into the optimal management of complications arising during primary PCI. It addresses critical scenarios from initial hesitation and unexpected challenges to confident treatment strategies for vessel complications. Notably, it explores complex cases such as paradoxical embolisation following rescue PCI in STEMI patients, providing...
Managing difficult TAVI scenarios
19 May 2026 – From EuroPCR 2026
Focused on complex TAVI cases, this session reviews guideline recommendations for TAVI in younger patients, strategies for managing concomitant coronary artery disease, and considerations for treating asymptomatic severe aortic stenosis. Real-world cases illustrate clinical decision-making and outcomes.
Risk stratification and drug therapies in coronary arteries interventions
19 May 2026 – From EuroPCR 2026
This session offers a detailed examination of risk stratification and pharmacologic therapies in coronary artery interventions. It features innovative markers such as left ventricle filling pressure (E/E' ratio) for predicting myocardial injury, clinical outcome impacts in dialysis-dependent patients, intraoperative DOAC removal during CABG, and machine learning...
Improving interventional care and occupational safety
19 May 2026 – From EuroPCR 2026
This session addresses advancements in interventional cardiology care quality and occupational safety. Key topics include patient-centered care perspectives, optimized catheterization lab scheduling, the impact of procedural volumes on outcomes, and innovations in radiation protection technologies.
High-risk PCI: how to optimise the result
19 May 2026 – From EuroPCR 2026
Focused on high-risk PCI, this session presents strategies to optimize procedural outcomes in complex cases. Discussions include contemporary approaches to challenging coronary anatomy, the role of balloon aortic valvuloplasty as a bridge to Impella-supported interventions, advanced mechanical support and thrombectomy in cardiogenic shock related to left...
Beyond valves: expanding the structural toolbox
19 May 2026 – From EuroPCR 2026
This session expands the scope of structural heart interventions beyond valve therapies. It covers embolic protection in high-risk intracardiac procedures, outcomes of paravalvular leak closures, novel aortic root stent-graft research, cerebral ischemia predictors after TEVAR, and transcatheter ASD closure techniques.
Choosing the right tool to treat calcified bifurcation
19 May 2026 – From EuroPCR 2026
This session provides expert guidance on managing calcified bifurcation lesions. It highlights identification of high-risk scenarios, the role of coronary CT angiography and intravascular imaging in tool selection, and specialized techniques for treating calcified nodules in the left main coronary artery.
Outcomes in tricuspid valve intervention
19 May 2026 – From EuroPCR 2026
This session reviews contemporary clinical outcomes of tricuspid valve interventions. Topics include interim results from the Cardiovalve replacement system trial, the impact of atrial fibrillation on tricuspid TEER, residual regurgitation implications, afterload mismatch post-intervention, and long-term bioprosthetic valve durability.
Addressing complications in calcified lesions
19 May 2026 – From EuroPCR 2026
This session delves into the complexities and management strategies for complications arising in calcified coronary lesions. Topics include advanced techniques such as puncturing the seal, handling lethal complications on calcified vessels, managing rare rotational atherectomy wire fractures, addressing massive stent deformation due to jailed rotawires, innovative...
The thin line between success and failure in MedTech start ups - Lessons learnt
18 May 2026 – From EuroPCR 2026
This session examines critical success factors for MedTech start-ups through real-world examples, discussing challenges, investment dynamics, and the pivotal role of the Chief Medical Officer and investor syndicates in fostering sustainable growth.